BIOMARKER:

MET amplification + EGFR mutation

Entrez ID:

Related biomarkers:

‹

›

MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib + tepotinib Sensitive: C3 – Early Trials	gefitinib + tepotinib Sensitive: C3 – Early Trials
MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib + capmatinib Sensitive: C3 – Early Trials	gefitinib + capmatinib Sensitive: C3 – Early Trials
MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	MET amplification + EGFR mutation MET amplification + EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: D – Preclinical	osimertinib Resistant: D – Preclinical